July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
A combined treatment approach emphasizing neuroprotective effects in a rat model of anterior ischemic optic neuropathy (rAION)
Author Affiliations & Notes
  • Yao-Tseng Wen
    Buddhist Tzu Chi General Hospital, Hualien, Taiwan
  • Rong-Kung Tsai
    Buddhist Tzu Chi General Hospital, Hualien, Taiwan
  • Wei Lin
    Optometry, Central Taiwan University of Science and Technology, Taichung, Taiwan
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2500. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yao-Tseng Wen, Rong-Kung Tsai, Wei Lin; A combined treatment approach emphasizing neuroprotective effects in a rat model of anterior ischemic optic neuropathy (rAION)
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):2500.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Granulocyte-colony-stimulating factor (G-CSF) has been reported to show a good neuroprotective effect in the rat model of anterior ischemic optic neuropathy (rAION). The anti-inflammatory action of G-CSF plays an important role in optic nerve (ON) protection. Accordingly, enhancement of anti-inflammatory action is a potential strategy in treatment of ischemic ON injury. The purpose of this study is to combine a nonsteroidal anti-inflammatory drug (Meloxicam) and G-CSF to improve the anti-inflammatory action for getting better therapeutic effects in the rAION model.

Methods : The rAION-inducted rats were treated with G-CSF only, Meloxicam only, or G-CSF plus Meloxicam. Four weeks after rAION induction, the visual protection and RGC protection were determined by measuring Flash-VEP and RGC density. The anti-apoptotic effect was measured by using TUNEL assay. The ON inflammation was evaluated by immunohistochemistry of ED1 staining.

Results : The amplitude of P1-N2 in the G-CSF plus Meloxicam-treated group was higher than those of the Meloxicam-treated group (p<0.05) and the G-CSF-treated group. The RGC density in the G-CSF plus Meloxicam-treated group was 1.6- and 1.3-fold of higher than those of the Meloxicam-treated group (p<0.05) and the G-CSF-treated group (p<0.05).The combined treatment decreased 3.5- (p<0.05) and 1.8-fold of the number of apoptotic RGC compared to treatment with Meloxicam only or G-CSF only. The combined treatment reduced the level of extrinsic macrophage infiltration more than treatment with Meloxicam only (p<0.05) or G-CSF only (p<0.05).

Conclusions : The combined treatment enhanced the anti-inflammatory action to preserve more RGCs and visual function in the rAION model. This combination approach provides crucial pre-clinical information for development of alternative therapy in non-arteritic aterior ischemic optic neuropathy.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×